Literature DB >> 21172881

Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.

Steven J Isakoff, Jose Baselga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21172881     DOI： 10.1200/JCO.2010.31.6679

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

1.  Girdin protein: a new potential distant metastasis predictor of breast cancer.

Authors:  Caigang Liu; Yanjun Zhang; Hong Xu; Ruishan Zhang; Hua Li; Ping Lu; Feng Jin
Journal:  Med Oncol       Date:  2011-11-25       Impact factor: 3.064

Review 2.  Molecular prescreening to select patient population in early clinical trials.

Authors:  Jordi Rodón; Cristina Saura; Rodrigo Dienstmann; Ana Vivancos; Santiago Ramón y Cajal; José Baselga; Josep Tabernero
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

Review 3.  Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?

Authors:  Eleonora Teplinsky; Francisco J Esteva
Journal:  Curr Oncol Rep       Date:  2015-10       Impact factor: 5.075

Review 4.  Perspectives of HER2-targeting in gastric and esophageal cancer.

Authors:  James N Gerson; Sam Skariah; Crystal S Denlinger; Igor Astsaturov
Journal:  Expert Opin Investig Drugs       Date:  2017-05       Impact factor: 6.206

Review 5.  Antibody-DM1 conjugates as cancer therapeutics.

Authors:  Manu Lopus
Journal:  Cancer Lett       Date:  2011-04-09       Impact factor: 8.679

Review 6.  Advances in systemic therapy for metastatic breast cancer: future perspectives.

Authors:  S P Corona; N Sobhani; A Ianza; G Roviello; G Mustacchi; M Bortul; F Zanconati; D Generali
Journal:  Med Oncol       Date:  2017-05-19       Impact factor: 3.064

7.  Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.

Authors:  E M Olson; N U Lin; P J DiPiro; J S Najita; I E Krop; E P Winer; H J Burstein
Journal:  Ann Oncol       Date:  2011-04-29       Impact factor: 32.976

8.  Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.

Authors:  Erin M Olson; Julie S Najita; Jessica Sohl; Amal Arnaout; Harold J Burstein; Eric P Winer; Nancy U Lin
Journal:  Breast       Date:  2013-01-23       Impact factor: 4.380

9.  Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy.

Authors:  Yun Yang; Qingcheng Guo; Xi Chen; Junjie Zhang; Huaizu Guo; Weizhu Qian; Sheng Hou; Jianxin Dai; Bohua Li; Yajun Guo; Hao Wang
Journal:  MAbs       Date:  2016       Impact factor: 5.857

Review 10.  Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer.

Authors:  Drew R Oostra; Erin R Macrae
Journal:  Breast Cancer (Dove Med Press)       Date:  2014-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.